Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,635 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of Changes in Pulmonary Function After Stereotactic Body Radiation Therapy Versus Conventional 3-Dimensional Conformal Radiation Therapy for Stage I and IIA Non-Small Cell Lung Cancer: An Analysis of the TROG 09.02 (CHISEL) Phase 3 Trial.
Bucknell NW, Kron T, Herschtal A, Hardcastle N, Irving L, MacManus M, Hanna GG, Moore A, Murnane A, Siva S, Ball D; CHISEL coauthors. Bucknell NW, et al. Among authors: moore a. Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):378-386. doi: 10.1016/j.ijrobp.2023.04.009. Epub 2023 Apr 21. Int J Radiat Oncol Biol Phys. 2023. PMID: 37087060 Clinical Trial.
Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial.
Siva S, Bressel M, Mai T, Le H, Vinod S, de Silva H, Macdonald S, Skala M, Hardcastle N, Rezo A, Pryor D, Gill S, Higgs B, Wagenfuehr K, Montgomery R, Awad R, Chesson B, Eade T, Wong W, Sasso G, De Abreu Lourenco R, Kron T, Ball D, Neeson P; Stereotactic Ablative Fractionated Radiotherapy Versus Radiosurgery for Oligometastatic Neoplasia to the Lung (SAFRON) II Study Investigators. Siva S, et al. JAMA Oncol. 2021 Oct 1;7(10):1476-1485. doi: 10.1001/jamaoncol.2021.2939. JAMA Oncol. 2021. PMID: 34455431 Free PMC article. Clinical Trial.
SEAFARER - A new concept for validating radiotherapy patient specific QA for clinical trials and clinical practice.
Lehmann J, Hussein M, Barry MA, Siva S, Moore A, Chu M, Díez P, Eaton DJ, Harwood J, Lonski P, Claridge Mackonis E, Meehan C, Patel R, Ray X, Shaw M, Shepherd J, Smyth G, Standen TS, Subramanian B, Greer PB, Clark CH. Lehmann J, et al. Among authors: moore a. Radiother Oncol. 2022 Jun;171:121-128. doi: 10.1016/j.radonc.2022.04.019. Epub 2022 Apr 21. Radiother Oncol. 2022. PMID: 35461949
Impact on Pulmonary Function in a Randomized Trial of Single-Fraction and Multifraction Stereotactic Body Radiation Therapy for Pulmonary Oligometastatic Disease: An Analysis of TROG 13.01 (SAFRON II).
Bucknell NW, Hardcastle N, Bressel M, Moore A, Montgomery R, Murnane A, Mai GT, Ball D, Kron T, Siva S. Bucknell NW, et al. Among authors: moore a. Int J Radiat Oncol Biol Phys. 2024 Mar 15;118(4):944-951. doi: 10.1016/j.ijrobp.2023.09.052. Epub 2023 Oct 21. Int J Radiat Oncol Biol Phys. 2024. PMID: 37871885 Clinical Trial.
Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial.
Siva S, Bressel M, Sidhom M, Sridharan S, Vanneste BGL, Davey R, Montgomery R, Ruben J, Foroudi F, Higgs B, Lin C, Raman A, Hardcastle N, Hofman MS, De Abreu Lourenco R, Shaw M, Mancuso P, Moon D, Wong LM, Lawrentschuk N, Wood S, Brook NR, Kron T, Martin J, Pryor D; FASTRACK II Investigator Group. Siva S, et al. Lancet Oncol. 2024 Mar;25(3):308-316. doi: 10.1016/S1470-2045(24)00020-2. Lancet Oncol. 2024. PMID: 38423047 Clinical Trial.
[18]F-fluoroethyl-l-tyrosine positron emission tomography for radiotherapy target delineation: Results from a Radiation Oncology credentialing program.
Barry N, Koh ES, Ebert MA, Moore A, Francis RJ, Rowshanfarzad P, Hassan GM, Ng SP, Back M, Chua B, Pinkham MB, Pullar A, Phillips C, Sia J, Gorayski P, Le H, Gill S, Croker J, Bucknell N, Bettington C, Syed F, Jung K, Chang J, Bece A, Clark C, Wada M, Cook O, Whitehead A, Rossi A, Grose A, Scott AM. Barry N, et al. Among authors: moore a. Phys Imaging Radiat Oncol. 2024 Mar 13;30:100568. doi: 10.1016/j.phro.2024.100568. eCollection 2024 Apr. Phys Imaging Radiat Oncol. 2024. PMID: 38585372 Free PMC article.
Dose-Effect Relationship of Kidney Function After SABR for Primary Renal Cell Carcinoma.
Gaudreault M, Hardcastle N, Jackson P, McIntosh L, Higgs B, Pryor D, Sidhom M, Dykyj R, Moore A, Kron T, Siva S. Gaudreault M, et al. Among authors: moore a. Int J Radiat Oncol Biol Phys. 2024 Apr 26:S0360-3016(24)00564-9. doi: 10.1016/j.ijrobp.2024.04.066. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 38679212
Head and Neck Cancer International Group (HNCIG) Consensus Guidelines for the Delivery of Postoperative Radiation Therapy in Complex Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN).
Porceddu SV, Daniels C, Yom SS, Liu H, Waldron J, Gregoire V, Moore A, Veness M, Yao M, Johansen J, Mehanna H, Rischin D, Le QT. Porceddu SV, et al. Among authors: moore a. Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):641-651. doi: 10.1016/j.ijrobp.2020.03.024. Epub 2020 Apr 11. Int J Radiat Oncol Biol Phys. 2020. PMID: 32289475
AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A, Lee M, Le H, Wilson K, Aiken C, Chantrill L, Simes J, Nguyen N, Barbour A, Samra J, Sjoquist KM, Moore A, Espinoza D, Gebski V, Yip S, Chu J, Kneebone A, Goldstein D. Oar A, et al. Among authors: moore a. BMC Cancer. 2021 Aug 19;21(1):936. doi: 10.1186/s12885-021-08666-y. BMC Cancer. 2021. PMID: 34412605 Free PMC article.
6,635 results